BioNTech SE (BNTX) Reports Q1 EPS of EUR14.24, Reiterates FY22 Guidance

BioNTech SE (NASDAQ: BNTX) reported Q1 EPS of EUR14.24. Revenue for the quarter came in at EUR6.4 billion.

The company reiterated COVID-19 2022 vaccine revenue guidance of €13 billion to €17 billion.

For earnings history and earnings-related data on BioNTech SE (BNTX) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• Investing.com’s stocks of the week
• Wells Fargo cuts Netflix rating on engagement risk, weak slate